Duchemann B[au] - Search Results

Year	Number of Results
2012	3
2013	2
2014	1
2015	3
2016	1
2017	3
2018	5
2019	10
2020	13
2021	5

1

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Ferrara R, et al. Among authors: duchemann b. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676. JAMA Oncol. 2018. PMID: 30193240 Free PMC article.

2

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.

Duchemann B, Remon J, Naigeon M, Mezquita L, Ferrara R, Cassard L, Jouniaux JM, Boselli L, Grivel J, Auclin E, Desnoyer A, Besse B, Chaput N. Duchemann B, et al. Cancers (Basel). 2020 Dec 3;12(12):3625. doi: 10.3390/cancers12123625. Cancers (Basel). 2020. PMID: 33287347 Free PMC article. Review.

3

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.

Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E. Mehlman C, et al. Among authors: duchemann b. Lung Cancer. 2019 Nov;137:149-156. doi: 10.1016/j.lungcan.2019.09.019. Epub 2019 Sep 28. Lung Cancer. 2019. PMID: 31600593

4

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.

Gobbini E, Toffart AC, Pérol M, Assié JB, Duruisseaux M, Coupez D, Dubos C, Westeel V, Delaunay M, Guisier F, Veillon R, Gounant V, Giroux Leprieur E, Vanel FR, Chaabane N, Dansin E, Babey H, Decroisette C, Barlesi F, Daniel C, Fournel P, Mezquita L, Oulkhouir Y, Canellas A, Duchemann B, Molinier O, Alcazer V, Moro-Sibilot D, Levra MG. Gobbini E, et al. Among authors: duchemann b. Clin Lung Cancer. 2020 Sep;21(5):e497-e510. doi: 10.1016/j.cllc.2020.04.013. Epub 2020 May 8. Clin Lung Cancer. 2020. PMID: 32605892

5

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B. Hendriks LEL, et al. Among authors: duchemann b. J Thorac Oncol. 2019 Jul;14(7):1244-1254. doi: 10.1016/j.jtho.2019.02.009. Epub 2019 Feb 16. J Thorac Oncol. 2019. PMID: 30780002 Free article.

6

Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.

Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Mezquita L, Texier M, Caramella C, Hendriks L, Planchard D, Remon J, Sangaletti S, Proto C, Garassino MC, Soria JC, Marabelle A, Voisin AL, Farhane S, Besse B, Chaput N. Ferrara R, et al. Among authors: duchemann b. Clin Cancer Res. 2021 Jan 15;27(2):492-503. doi: 10.1158/1078-0432.CCR-20-1420. Epub 2020 Sep 4. Clin Cancer Res. 2021. PMID: 32887723

7

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis.

Landre T, Chouahnia K, Des Guetz G, Duchemann B, Assié JB, Chouaïd C. Landre T, et al. Among authors: duchemann b. Ther Adv Med Oncol. 2020 Dec 9;12:1758835920977137. doi: 10.1177/1758835920977137. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33343721 Free PMC article.

8

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.

Landre T, Des Guetz G, Chouahnia K, Duchemann B, Assié JB, Chouaid C. Landre T, et al. Among authors: duchemann b. J Cancer Res Clin Oncol. 2020 Dec;146(12):3333-3339. doi: 10.1007/s00432-020-03311-w. Epub 2020 Jul 7. J Cancer Res Clin Oncol. 2020. PMID: 32632581

9

Pulmonary Sarcoidosis.

Valeyre D, Bernaudin JF, Jeny F, Duchemann B, Freynet O, Planès C, Kambouchner M, Nunes H. Valeyre D, et al. Among authors: duchemann b. Clin Chest Med. 2015 Dec;36(4):631-41. doi: 10.1016/j.ccm.2015.08.006. Clin Chest Med. 2015. PMID: 26593138 Review.

10

Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, Sanyal S, Brillet PY, Brauner M, Kambouchner M, Huynh S, Naccache JM, Borie R, Piquet J, Mekinian A, Virally J, Uzunhan Y, Cadranel J, Crestani B, Fain O, Lhote F, Dhote R, Saidenberg-Kermanac'h N, Rosental PA, Valeyre D, Nunes H. Duchemann B, et al. Eur Respir J. 2017 Aug 3;50(2):1602419. doi: 10.1183/13993003.02419-2016. Print 2017 Aug. Eur Respir J. 2017. PMID: 28775045 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results